Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen® for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time Dec 19, 2014
Xenetic Biosciences CEO Delivers “2014 – The Year in Review” Update to Investors and Stakeholders Dec 18, 2014
Xenetic Biosciences Announces OncoHist™ Preclinical Data to be Featured in a Poster Presentation at the American Society of Hematology Annual Meeting Dec 4, 2014
Xenetic Biosciences Partner Completes Dosing of Second Cohort in Phase 2a Study of ErepoXen® in Patients with Chronic Kidney Disease on Dialysis Dec 2, 2014
Xenetic Biosciences Provides Update on Substantial Patent Grants and Allowances in U.S. and Worldwide Nov 25, 2014
Xenetic Biosciences Partner Completes First Patient Cohort in Phase 2 Study with MyeloXen™ for Multiple Sclerosis Nov 21, 2014
Xenetic Biosciences to Hold Business Update Conference Call September 23 at 6:00 a.m. Eastern Time Sep 22, 2014
Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R) Aug 11, 2014
Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R) Jun 11, 2014
